- Home
- SCLX vs CCEL Comparison
SCLX vs CCEL Comparison
Compare SCLX & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLX
- CCEL
- Stock Information
- Founded
- SCLX 2011
- CCEL 1989
- Country
- SCLX United States
- CCEL United States
- Employees
- SCLX N/A
- CCEL N/A
- Industry
- SCLX Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- SCLX Health Care
- CCEL Health Care
- Exchange
- SCLX Nasdaq
- CCEL Nasdaq
- Market Cap
- SCLX 35.7M
- CCEL 34.8M
- IPO Year
- SCLX N/A
- CCEL 1997
- Fundamental
- Price
- SCLX $16.46
- CCEL $4.35
- Analyst Decision
- SCLX Buy
- CCEL Hold
- Analyst Count
- SCLX 2
- CCEL 1
- Target Price
- SCLX $245.00
- CCEL N/A
- AVG Volume (30 Days)
- SCLX 255.7K
- CCEL 6.2K
- Earning Date
- SCLX 08-13-2025
- CCEL 10-15-2025
- Dividend Yield
- SCLX N/A
- CCEL 14.94%
- EPS Growth
- SCLX N/A
- CCEL N/A
- EPS
- SCLX N/A
- CCEL N/A
- Revenue
- SCLX $44,236,000.00
- CCEL $31,747,500.00
- Revenue This Year
- SCLX $89.26
- CCEL $1.75
- Revenue Next Year
- SCLX $203.95
- CCEL N/A
- P/E Ratio
- SCLX N/A
- CCEL N/A
- Revenue Growth
- SCLX N/A
- CCEL N/A
- 52 Week Low
- SCLX $3.60
- CCEL $4.09
- 52 Week High
- SCLX $39.90
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- SCLX 47.62
- CCEL 41.26
- Support Level
- SCLX $13.08
- CCEL $4.35
- Resistance Level
- SCLX $14.74
- CCEL $4.54
- Average True Range (ATR)
- SCLX 1.51
- CCEL 0.16
- MACD
- SCLX -0.07
- CCEL -0.01
- Stochastic Oscillator
- SCLX 55.24
- CCEL 1.71
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.